Eli Lilly to spend nearly $4 billion on vaccine deals in infectious-disease push
Eli Lilly says it plans nearly $4 billion in vaccine deals as it expands into infectious-disease research and development, according to CNBC. The push would broaden a portfolio long anchored by obesity and diabetes drugs. Its shares edged higher after the announcement.
Eli Lilly said it plans to spend nearly $4 billion on a set of vaccine deals as the drugmaker pushes into infectious-disease research and development, according to CNBC. The agreements, which the company tied to partnerships with biotech firms working on vaccine candidates, would broaden Lilly's portfolio well beyond the obesity and diabetes treatments that have driven its recent growth.
The move signals Lilly's intent to compete in a field long dominated by larger vaccine specialists. Investors responded cautiously positively, with the stock edging higher after the announcement. Analysts cited by CNBC framed the spending as a long-term bet on diversifying revenue rather than an immediate earnings driver.
The company has not detailed when the acquired or licensed programmes might reach the market, and several remain in early-stage development. This article is for information only and is not investment advice.
More from North America
US stocks open higher on Iran-deal hopes, led by a relentless Micron and tech rally
US stocks opened higher on hopes that an Iran deal may be near, led by a continued Micron-fuelled tech rally, CNBC reports. The S&P 500 rose 0.9% last week to extend its longest weekly winning streak since late 2023.
UAE says OPEC exit was a strategic economic move, not political
The United Arab Emirates said its decision to leave OPEC was a strategic economic choice rather than a political one. Officials told CNBC the move lets the country deploy spare production capacity freely and align output with its energy diversification plans.
BlackRock weighs $5-10 billion investment in SpaceX IPO
BlackRock is in talks to commit between $5 billion and $10 billion to SpaceX's upcoming initial public offering, The Information reported. The investment, if completed, would mark one of the largest single-firm commitments to a US listing in years.